# Heptares Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heptares-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Welwyn Garden City, UK
- Website: www.heptares.com
- Total disclosed funding: $70M
- Latest round: Series B (Jun 13, 2013)
- Investors on record: 5

## About

Heptares Therapeutics Ltd is a biopharmaceutical company that focuses on drug discovery and development, particularly leveraging its proprietary technology in structure-based drug design to create therapies for challenging diseases.Heptares Therapeutics Ltd specializes in drug discovery and development, utilizing its unique expertise in structure-based drug design to create innovative therapies. Founded in 2007, the company is headquartered in Welwyn Garden City, UK. In February 2015, Heptares was acquired by Sosei Co., Ltd. for USD 400 mn, marking a significant milestone in its operational strategy. The firm has completed eight deals to date, indicative of its active engagement in the biopharmaceutical market.Heptares Therapeutics develops innovative pharmaceuticals aimed at addressing unmet medical needs using advanced structure-based drug design. The company's portfolio of therapies targets various therapeutic areas, including oncology, neurology, and infectious diseases, primarily serving healthcare providers, hospitals, and specialty pharmacies across North America, Europe, and select Asian markets.In the most recent fiscal year of 2023, Heptares Therapeutics reported a revenue of USD 35.22 mn, with an EBITDA of USD -37.23 mn. The company generates its revenue through strategic partnerships and direct sales of its pharmaceutical products, engaging in B2B transactions with healthcare institutions and distributors.Heptares Therapeutics aims to leverage its recent acquisition by Sosei Co., Ltd. to expand its product pipeline and enhance its market presence. The company is focusing on developing new pharmaceuticals that are currently in the design phase, with plans to launch these products in the coming years. Additionally, Heptares intends to expand into new geographic markets, targeting growth in regions that align with its therapeutic focus. The strategic use of the USD 400 mn from the trade sale will support these initiatives, facilitating research and development efforts and establishing new partnerships.

## Funding rounds

- Series B, Jun 13, 2013, $22M — Clarus Ventures, Stanley Medical Research Institute, Takeda Ventures
- Series A, Mar 31, 2011, $16M — Takeda Ventures
- Series A, Feb 24, 2009, $30M — MVM Partners, Novartis Venture Fund, Clarus Ventures
- Seed, Feb 8, 2008, $2M — MVM Partners
- Seed, Aug 10, 2007 — MVM Partners

## Investors

- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Seed, Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series A, Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A, Series B
- Stanley Medical Research Institute — Series B